Eli Lilly Inventory Turnover Ratio 2010-2023 | LLY

Current and historical inventory turnover ratio for Eli Lilly (LLY) from 2010 to 2023. Inventory turnover ratio can be defined as a ratio showing how many times a company's inventory is sold and replaced over a period. Eli Lilly inventory turnover ratio for the three months ending December 31, 2023 was 0.31.
Eli Lilly Inventory Turnover Ratio Historical Data
Date
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $695.710B $34.124B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Novo Nordisk (NVO) Denmark $566.147B 46.64
Johnson & Johnson (JNJ) United States $357.925B 14.20
Merck (MRK) United States $321.695B 84.67
AbbVie (ABBV) United States $297.115B 15.10
AstraZeneca (AZN) United Kingdom $220.752B 19.56
Novartis AG (NVS) Switzerland $201.027B 14.25
Pfizer (PFE) United States $148.755B 14.35
Sanofi (SNY) $117.905B 10.62
Innoviva (INVA) United States $0.959B 6.77